Generate Biomedicines (GENB) files for proposed IPO
Get Alerts GENB Hot Sheet
Join SI Premium – FREE
Generate Biomedicines (GENB) has filed for a proposed Nasdaq IPO.
The company describes itself as: "We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. We have built our Generate Platform to be a tight and fully-integrated loop (design–build–test–learn) to create proprietary, therapeutically relevant data and differentiated molecular solutions for the biological challenges we aim to address. In addressing these challenges, the Generate Platform can engineer solutions against therapeutic targets by either starting from existing reference proteins or suggesting completely novel ones without a reference starting point, also known as de novo design. The Generate Platform’s therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody, which is enrolling patients in pivotal Phase 3 clinical trials for severe asthma. The first patient was dosed in one of the Phase 3 clinical trials on January 26, 2026. We also expect to advance two additional computationally generated oncology product candidates into Phase 1 clinical trials in 2026."
Goldman Sachs and Morgan Stanley will serve as lead underwriters.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
- JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
Corporate News, IPOsRelated Entities
Goldman Sachs, Morgan Stanley, IPO, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share